Trim-edicine, Inc.

North Brunswick, NJ 08902

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $4.13MM
First Award Date 08/20/10
Most Recent Award Date 09/01/17

Key Personnel

Last Name Name Awards Contact
Takizawa Norio Takizawa 3
Sheng Zelin Sheng 2 Message
TAN TAO TAN 4

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/01/17 - 08/31/18
PI: TAO TAN

Project Summary This direct Phase II SBIR proposal focuses on the development of recombinant human MG53 (rhMG53), a novel tissue repair protein, as a therapeutic candidate targeting injury of renal epithelium to protect against acute kidney injury (AKI). AKI is commonly encountered in the hospital and outpatient settings and is associated with a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 07/01/17 - 06/30/18
PI: TAO TAN

Project Summary This Phase I SBIR proposal targets the development of recombinant human MG53 (rhMG53), a novel tissue repair protein, as a topical therapeutic candidate to facilitate healing of chronic wounds. Wound care represents a challenging problem to the public health, as no effective treatments for chronic non-healing wounds are available...

Unknown

ConProject-001

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 07/01/17 - 06/30/18
PI: TAO TAN

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/15/16 - 08/31/17
PI: TAO TAN

Project Summary This direct Phase II SBIR proposal focuses on the development of recombinant human MG53 (rhMG53), a novel tissue repair protein, as a therapeutic candidate targeting injury of renal epithelium to protect against acute kidney injury (AKI). AKI is commonly encountered in the hospital and outpatient settings and is associated with a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 08/01/14 - 07/31/15

DESCRIPTION (provided by applicant): While organ transplantation is a vital last resort therapy to treat patients with end-organ failure of the lung there is a growing waiting list of patients who are eligible for transplants as the number of suitable donor organs fall far short of the demand for these lifesaving procedures. Improving the preser...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/26/13 - 08/31/14

DESCRIPTION (provided by applicant): Development of novel therapeutics that can induce apoptosis by directly targeting the Bcl-2 family proteins has been a major focus of cancer research. Several groups have developed BH3 peptides derived from pro- apoptotic Bcl-2 family proteins or produced chemical compounds that could act as BH3 peptidomimeti...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 08/01/13 - 07/31/14

DESCRIPTION (provided by applicant): SBIR 1R43AR060019 Phase II application: "Protein Therapeutics for Muscular Dystrophy" Principal Investigator: Takizawa, Norio Project Summary: This application requests for a Phase II project for our initial SBIR grant addressing the use of a novel protein therapeutic agent, MG53, for the treatment of mu...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 08/01/12 - 07/31/13

DESCRIPTION (provided by applicant): SBIR 1R43AR060019 Phase II application: "Protein Therapeutics for Muscular Dystrophy" Principal Investigator: Takizawa, Norio Project Summary: This application requests for a Phase II project for our initial SBIR grant addressing the use of a novel protein therapeutic agent, MG53, for the treatment of mu...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AR-10-004
Budget: 08/20/10 - 08/19/11

DESCRIPTION (provided by applicant): Defective membrane repair is associated with the progression of muscular dystrophy that is linked to mutations in caveolin-3 (Cav3) and dysferlin in human patients. Several other forms of muscular dystrophy, including Duchenne muscular dystrophy and dystrophy arising from mutations in the dystroglycan complex...